研究業績 2025年

  • Toyoda Y, Saito H, Hirata H, Ota-Kontani A, Tsuchiya Y, Takada T. Investigation of the Inhibitory Effects of Fatty Acid Derivatives on URAT1 Function, a Renal Urate Re-Absorber. J Nutr Sci Vitaminol 2025 71(4):331-338. [open access]
  • Fujiwara T, Kariya Y, Kobayashi K, Matsui S, Takada T. Utility of the continuous spectrum formed by pathological states in characterizing disease properties. NPJ Syst Biol Appl 2025 11(1):100. [open access]
  • Wakimoto Y, Okamoto K, Yamamoto T, Akamatsu N, Kariya T, Hoshino Y, Harada S, Hashimoto H, Jubishi D, Tanaka T, Yamaguchi R, Kaneko J, Okugawa S, Takada T, Hasegawa K, Uchida K, Tsutsumi T. The effect of intraoperative excessive bleeding on the pharmacokinetics of ampicillin and sulbactam in recipients of living donor liver transplantation in Japan. JAC Antimicrob Resist 2025 7(4):dlaf149. [abstract]
  • Yamaguchi R, Yamamoto T, Harada S, Shibuya M, Mizoguchi M, Higurashi Y, Echizenya M, Tsutsumi T, Takada T. Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible Enterococcus faecium bacteraemia. JAC Antimicrob Resist 2025 7(4):dlaf151. [open access]
  • Kurokawa Y, Kawai T, Taguchi S, Honda K, Maki K, Ambe Y, Saegusa N, Yamamoto M, Tokura Y, Yanagida K, Takei K, Inoue H, Tanaka T, Nara K, Kaneko T, Fujii Y, Miyakawa J, Kamei J, Kakutani S, Niimi A, Yamada D, Yamada Y, Takada T, Nakagawa T, Kume H. Predictive ability of the geriatric 8 screening tool for treatment completion of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy in patients with urothelial carcinoma. Jpn J Clin Oncol 2025 hyaf105m. [open access]
  • Toyoda Y, Shigesawa R, Merriman TR, Matsuo H, Takada T. GLUT2/SLC2A2 is a bi-directional urate transporter. J Biol Chem 2025 in press. [open access]
  • Matsushita D, Toyoda Y, Lee Y, Maeda A, Matsuo H, Takada T, Nishizawa T. Structural basis of urate transport by glucose transporter 9. Cell Rep 2025 44(4):115514. [open access] [プレスリリース (共同発表：横浜市立大学・東京大学・防衛医科大学校)]
  • Toyoda Y, Pavelcova K, Masinova J, Hasikova L, Zavada J, Hanova P, Klein M, Vavra J, Takada T, Stiburkova B. Identification of pathogenic variants in the ABCG2 gene in patients with severe familial hyperuricemia and gout. Mol Cell Biochem 2025 in press. [abstract]
  • Taguchi S, Kawai T, Kurokawa Y, Saegusa N, Yamamoto M, Ambe Y, Honda K, Maki K, Fujii Y, Miyakawa J, Tokura Y, Inoue H, Kaneko T, Tanaka T, Nara K, Kamei J, Kakutani S, Yamada Y, Niimi A, Yamada D, Takada T, Nakagawa T, Kume H. The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study. Int J Clin Oncol 2025 in press. [open access]
  • Ito SM, Yamanashi Y, Suzuki H, Takada T. Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes. Biochem Pharmacol 2025 233:116778. [open access]
  • Miyata Y, Yamaguchi R, Yamamoto T, Kishida T, Ikeuchi K, Harada H, Tsutsumi T, Fujio K, Takada T. Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report. J Pharm Health Care Sci 2025 11(1):3. [open access]
  • Morita K, Sato K, Tomabechi R, Yamaya R, Takada T, Kishimoto H, Higuchi K, Inoue K. Luciferase-based bioluminescence revealed the facilitated diffusion of D-luciferin mediated by SLC17A3. Biochem Biophys Res Commun 2025 749:151360. [abstract]
  • Kawai T, Kurokawa Y, Taguchi S, Honda K, Maki K, Ambe Y, Saegusa N, Yamamoto M, Miyakawa J, Tokura Y, Inoue H, Tanaka T, Nara K, Kaneko T, Fujii Y, Kamei J, Kakutani S, Yamada Y, Niimi A, Yamada D, Takada T, Nakagawa T, Kume H. Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinoma. Jpn J Clin Oncol in press. [abstract]
  • Matake I, Yasujima T, Matsuo H, Toyoda Y, Kawamura Y, Takada T, Inoue K, Yamashiro T, Yuasa H. Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate. Drug Metab Pharmacokinet in press. [open access]